跳到正文

Catalio Capital Management, LP 13F 持仓 · 2026年Q2

Catalio Capital Management 在 2026年Q2(报告期截至 2026-06-30)的 SEC 13F 申报中报告了 39 只证券,申报市值合计 5.32 亿美元。前几大持仓:AVLN(10.37%)、JNJ(6.63%)、GILD(6.39%)。本季前 25 大持仓中:新建仓 9 只、增持 12 只、减持 4 只。

排名代码公司市值占组合股数变动
1AVLNAVALYN PHARMACEUTICALS INC$55.2M10.37%1.7M新建仓
2JNJJOHNSON & JOHNSON$35.3M6.63%138,946新建仓
3GILDGILEAD SCIENCES INC$34.0M6.39%269,309增持
4BBIOBRIDGEBIO PHARMA INC$33.9M6.37%455,041增持
5SNDXSYNDAX PHARMACEUTICALS INC$26.6M4.99%1.2M增持
6DFTXDEFINIUM THERAPEUTICS INC$26.5M4.97%562,672减持
7BMYBRISTOL-MYERS SQUIBB CO$23.8M4.47%412,961减持
8PBLSPARABILIS MEDICINES INC$22.6M4.24%824,043新建仓
9NTRANATERA INC$22.3M4.19%82,181增持
10INCYINCYTE CORP$21.7M4.08%191,627增持
11SEPNSEPTERNA INC$18.0M3.37%536,152增持
12MLYSMINERALYS THERAPEUTICS INC$17.5M3.29%648,722增持
13HTFLHEARTFLOW INC$17.1M3.21%583,055增持
14CRVSCORVUS PHARMACEUTICALS INC$16.1M3.03%1.1M增持
15GPCRSTRUCTURE THERAPEUTICS INC$14.8M2.79%276,550增持
16PTGXPROTAGONIST THERAPEUTICS INC$13.1M2.46%106,799新建仓
17IRONDISC MEDICINE INC$11.7M2.19%159,384增持
18EWEDWARDS LIFESCIENCES CORP$11.3M2.12%124,778减持
19AXSMAXSOME THERAPEUTICS INC.$10.6M1.99%43,182新建仓
20RAREULTRAGENYX PHARMACEUTICAL IN$10.6M1.98%316,252减持
21KLRAKAILERA THERAPEUTICS INC$10.3M1.94%468,750新建仓
22KPTIKARYOPHARM THERAPEUTICS INC$9.2M1.73%940,855增持
23ODTXODYSSEY THERAPEUTICS INC$8.6M1.61%457,839新建仓
24ASNDASCENDIS PHARMA A/S$8.5M1.59%31,759新建仓
25KARDKARDIGAN INC$7.5M1.40%312,500新建仓

来源:SEC 13F 申报文件 · 截至 2026-06-30

本期 13F-HR 中的全部持仓,以及相对上季度的变化。

13F 持仓,最新季度

来源SEC EDGAR13F-HR